Both a misfolded form of the alpha-synuclein protein and an inflammatory cue are needed to trigger the Lewy bodies that drive the death of dopaminergic neurons in the brains of people with Parkinson’s disease, according to a study in human stem cells. “The results support previous research showing that…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second research grant of $2.5 million to Selonterra to advance the California-based company’s preclinical development of new therapeutic compounds targeting the genetic causes of Parkinson’s disease. Selonterra specifically will be testing whether compounds that…
New U.S. Department of Defense-funded research at Binghamton University in New York is investigating the underlying causes of neuropsychiatric symptoms — those that result from medical conditions involving both neurologic and psychiatric components — in people with Parkinson’s disease. The four-year grant, totaling $3 million, is shared between Binghamton,…
The Centre for Medicines Discovery at the University of Oxford and BPGbio, an artificial intelligence (AI)-focused biopharmaceutical company, established a five-year research collaboration that aims to advance new technologies for treatments for people with brain diseases like Parkinson’s who have limited options. Together the partners will validate and…
Gain Therapeutics has presented new preclinical data showing GT-02287, its experimental therapy for Parkinson’s disease, can slow disease progression in mouse and cellular models of the disease. Overall, the treatment was shown to improve motor function and coordination, and activities of daily living in mouse models of Parkinson’s…
A single dose of CAP-003, a gene therapy being developed by Capsida Biotherapeutic, significantly increased the levels of GCase enzyme in the brains of non-human primates. The enzyme levels reached up to eight times the amount considered necessary to restore normal enzyme activity in individuals with Parkinson’s disease…
Researchers at New York University (NYU) Langone Health were awarded a two-year, $1.6 million grant by the National Institutes of Health (NIH) to investigate eye changes as potential early signs and progression markers of Parkinson’s disease and Alzheimer’s. The grant, given under the NIH Common Fund Venture Program’s…
Irlab Therapeutics’ oral therapy IRL757 was safe and well tolerated in healthy volunteers in the first part of a Phase 1 study testing the therapy, a potential treatment for apathy in patients with Parkinson’s disease and other neurological conditions. “This bodes well for the further clinical development of a…
Two studies support the safety and tolerability of Nuplazid (pimavanserin) in older or frail adults with psychosis associated with Parkinson’s disease. Safety data on Nuplazid, the only medication approved by the U.S. Food and Drug Administration (FDA) to treat Parkinson’s-associated psychosis, were presented at this year’s International…
Aspen Neuroscience has opened a manufacturing facility for ANPD001, its investigational stem cell therapy for Parkinson’s disease being used in an ongoing Phase 1/2a clinical trial. The 22,000-square-foot facility is an expansion of the company’s headquarters near San Diego, and is reported to include three manufacturing suites certified…
Get regular updates to your inbox.
